Guideline Summary for Management of Stage 1 Acute Kidney Injury (AKI)

Definition & Diagnostic Criteria

Etiology Assessment

Initial Management Strategies (First‑Line for Stage 1 AKI)

Monitoring & Follow‑Up

Indications for Nephrology Referral & Renal Replacement Therapy (RRT)

RRT Modality Selection

KDIGO Criteria and Management of Acute Kidney Injury in Patients with Pre‑existing Chronic Kidney Disease

Diagnostic Criteria for AKI

• KDIGO defines Stage 1 AKI as a serum creatinine increase of ≥ 0.3 mg/dL within 48 hours or a rise to ≥ 1.5 × baseline within 7 days, warranting immediate evaluation and management. 8
• An absolute rise of ≥ 0.3 mg/dL within a 7‑day window satisfies AKI criteria even when the exact prior creatinine value is unknown. 8
• In a 79‑year‑old patient with CKD stage 3 (baseline typically 1.2–1.9 mg/dL), a current creatinine of 2.05 mg/dL represents a clinically significant absolute increase, meeting KDIGO AKI thresholds. 8

Determining Baseline Creatinine

• When a recent baseline creatinine is unavailable, KDIGO recommends estimating it using the MDRD equation assuming an eGFR of 75 mL/min/1.73 m². 8
• For accurate AKI staging in patients with CKD, the most recent outpatient creatinine measured within the prior 7–365 days should be obtained to establish the true baseline. 9
• In CKD stage 3, baseline creatinine values are already elevated above normal, which must be considered when applying AKI criteria. 10

Considerations for Acute‑on‑Chronic Kidney Disease (ACKD)

• In individuals with pre‑existing CKD, percentage increases in creatinine are often blunted, making absolute changes more reliable for detecting superimposed AKI. 10
• Acute‑on‑chronic kidney disease carries a markedly higher mortality risk; even modest, transient creatinine rises are associated with a 13–14 % in‑hospital mortality rate compared with ≈ 3 % in patients without AKI. 10
• Clinicians should avoid dismissing creatinine elevations as “just CKD” because the combination of chronic disease and acute injury substantially worsens outcomes. 10

Workup and Management of Stage 1 Acute Kidney Injury

Diagnostic Assessment

• Obtain prior serum creatinine values from the preceding 3–12 months to establish a true baseline and verify that the current rise represents an acute change rather than chronic kidney disease. 11
• Define Stage 1 AKI as either a rise in serum creatinine ≥ 0.3 mg/dL within 48 hours or a ≥ 1.5‑fold increase from baseline within 7 days. [11][12]
• Discontinue ACE‑inhibitors or ARBs when the serum creatinine rises > 30 % from baseline, as this magnitude of change signals a potentially nephrotoxic effect. [13][14]
• Hold diuretic therapy temporarily to allow accurate assessment of volume status. [15][11]
• Assess volume status clinically with orthostatic vital signs, mucous membrane moisture, skin turgor, and jugular venous pressure. [11][14]
• Identify recent vomiting, diarrhea, poor oral intake, or excessive diuresis as additional markers of volume depletion. 16
• Look for signs of heart failure (elevated JVP, peripheral edema, pulmonary crackles) that may indicate congestion‑related renal impairment. 15
• Perform a chest radiograph when respiratory symptoms are present to evaluate for pulmonary congestion or infection. 14
• Within 24 hours, obtain a urinalysis with microscopy; muddy‑brown granular casts suggest acute tubular necrosis, whereas red‑cell casts point toward glomerulonephritis. 16
• Measure urine albumin‑to‑creatinine ratio; values ≥ 30 mg/g denote kidney damage and guide long‑term management strategies. [13][16]
• Check serum electrolytes: hyper‑kalemia > 5.5 mmol/L warrants prompt intervention; low bicarbonate indicates metabolic acidosis. [13][14]
• Calculate fractional excretion of sodium (FENa):
  
  • FENa < 1 % favors a prerenal etiology. 11
  • FENa > 2 % supports intrinsic renal injury such as acute tubular necrosis. 17

Immediate Management

• Hold all nephrotoxic medications and initiate intravenous crystalloid infusion (normal saline or balanced solution) when clinical hypovolemia is identified, targeting euvolemia without fluid overload. 11
• Optimize hemodynamics by maintaining adequate blood pressure and avoiding hypotensive episodes. [15][14]

Monitoring Protocol

• Repeat serum creatinine and electrolyte panels within 48 hours to gauge trajectory; if stable or improving, schedule weekly checks until resolution. 17
• If creatinine worsens, perform daily laboratory reassessment and consider escalation of care. 17
• Monitor urine output; a sustained output < 0.5 mL/kg/h for > 6 hours signals progression to a higher AKI stage and is linked to increased mortality. 12

Criteria for Nephrology Referral

• Estimated glomerular filtration rate < 30 mL/min/1.73 m² (calculated with the CKD‑EPI equation). [13][16]
• Serum creatinine ≥ 3 × baseline or absolute value ≥ 4.0 mg/dL (Stage 3 AKI). 12
• Unclear etiology after initial work‑up. 13
• Rapidly progressive renal dysfunction (increase > 0.5 mg/dL per day). 13
• Severe complications: hyper‑kalemia > 6.0 mmol/L, severe metabolic acidosis, uremic manifestations, or refractory volume overload despite diuretics. 14

Absolute Indications for Renal Replacement Therapy

• Life‑threatening hyper‑kalemia unresponsive to medical therapy. 15
• Severe metabolic acidosis with pH < 7.1. 16
• Uremic complications such as pericarditis, encephalopathy, or bleeding. 13

Post‑AKI Follow‑Up

• Re‑measure serum creatinine at 3 months after AKI resolution to determine recovery versus progression to chronic kidney disease. 17
• Conduct annual urine albumin‑to‑creatinine ratio and eGFR screening in patients with diabetes and in all AKI survivors. [13][16]17
• Early nephrology consultation (within the first days of a rising creatinine) improves patient outcomes. [13][17]

Common Pitfalls to Avoid

• Do not discontinue ACE‑inhibitors/ARBs for creatinine rises < 30 % in the absence of volume depletion, as these agents provide long‑term renoprotection. [13][16]14